Bristol Myers Squibb's Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with schizophrenia.
The company said Tuesday a Phase 3 trial of Cobenfy as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale total score compared to a placebo with an atypical antipsychotic at week six.
The results missed the threshold for statistical significance for the primary endpoint, the company said.
Preliminary analyses suggest the treatment was associated with improved schizophrenia symptoms compared to the placebo treatment for certain patients.
A post-hoc subgroup analysis showed there was a notable difference in response between subjects treated with risperidone as a background therapy and those treated with other background antipsychotics.
The company said it plans to speak with regulators about potential next steps.
Shares fell 5.6% to $47.03 on Tuesday in after-hours trading. Shares have risen 1% over the last 12 months through Tuesday's close.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.